Search

Your search keyword '"Soiffer R"' showing total 421 results
Start Over Author "Soiffer R"

Refine your results

more »

more »

more »

more »
421 results on '"Soiffer R"'

51. Immune Reconstitution After Double Umbilical Cord Blood Stem Cell Transplantation: Comparison With Peripheral Blood Stem Cell Transplantation

Author

Jacobson, C., primary, Turki, A., additional, McDonough, S., additional, Stevenson, K., additional, Kim, H., additional, Herrera, M., additional, Reynolds, C., additional, Alyea, E., additional, Ho, V., additional, Koreth, J., additional, Soiffer, R., additional, Antin, J., additional, Ballen, K., additional, Cutler, C., additional, and Ritz, J., additional

Published
2011
Full Text
View/download PDF

53. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis

Author

Cutler, C, primary, Stevenson, K, additional, Kim, H T, additional, Brown, J, additional, McDonough, S, additional, Herrera, M, additional, Reynolds, C, additional, Liney, D, additional, Kao, G, additional, Ho, V, additional, Armand, P, additional, Koreth, J, additional, Alyea, E, additional, Dey, B R, additional, Attar, E, additional, Spitzer, T, additional, Boussiotis, V A, additional, Ritz, J, additional, Soiffer, R, additional, Antin, J H, additional, and Ballen, K, additional

Published
2010
Full Text
View/download PDF

54. Serologic Markers of Effective Tumor Immunity against Chronic Lymphocytic Leukemia Include Nonmutated B-Cell Antigens

Author

Marina, O., primary, Hainz, U., additional, Biernacki, M. A., additional, Zhang, W., additional, Cai, A., additional, Duke-Cohan, J. S., additional, Liu, F., additional, Brusic, V., additional, Neuberg, D., additional, Kutok, J. L., additional, Alyea, E. P., additional, Canning, C. M., additional, Soiffer, R. J., additional, Ritz, J., additional, and Wu, C. J., additional

Published
2010
Full Text
View/download PDF

58. Prediction of VOD Using Biomarkers of Endothelial Injury

Author

Cutler, C., primary, Aldridge, J., additional, Kim, H.T., additional, Ayanian, S., additional, Bradwin, G., additional, Revta, C., additional, Murga, G., additional, Ho, V., additional, Alyea, E., additional, Koreth, J., additional, Armand, P., additional, Richardson, P.G., additional, Soiffer, R., additional, Ritz, J., additional, and Antin, J.H., additional

Published
2009
Full Text
View/download PDF

59. A342 Endothelial Stress Markers in Multiple Myeloma Patients

Author

Richardson, PG, primary, Rosovsky, R, additional, Hong, F, additional, Tocco, D, additional, Connell, B, additional, Mitsiades, C, additional, Schlossman, R, additional, Ghobrial, IM, additional, Munshi, NC, additional, Lockridge, L, additional, Warren, D, additional, Bradwin, G, additional, Doyle, M, additional, Soiffer, R, additional, Anderson, KC, additional, Weller, E, additional, and Richardson, PG, additional

Published
2009
Full Text
View/download PDF

60. Prediction of VOD Using Biomarkers of Endothelial Injury.

Author

Cutler, Corey, primary, Aldridge, J., additional, Kim, H. T., additional, Ayanian, S., additional, Bradwin, G., additional, Revta, C., additional, Murga, G., additional, Ho, V., additional, Alyea, E., additional, Koreth, J., additional, Armand, P., additional, Richardson, P. G., additional, Soiffer, R. J., additional, Ritz, J., additional, and Antin, J. H., additional

Published
2008
Full Text
View/download PDF

62. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation

Author

Haspel, R L, primary, Kao, G, additional, Yeap, B Y, additional, Cutler, C, additional, Soiffer, R J, additional, Alyea, E P, additional, Ho, V T, additional, Koreth, J, additional, Dey, B R, additional, McAfee, S L, additional, Attar, E C, additional, Spitzer, T, additional, Antin, J H, additional, and Ballen, K K, additional

Published
2007
Full Text
View/download PDF

64. Defibrotide (DF) for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF.

Author

Richardson, Paul G., primary, Soiffer, R. J., primary, Antin, J. H., primary, Jin, Z., primary, Kurtzberg, J., primary, Martin, P. L., primary, Hockenbery, D., primary, Murray, K. F., primary, Vogelsang, G. B., primary, Chen, A., primary, Krishnan, A., primary, Kernan, N. A., primary, Avigan, D., primary, Spitzer, T. R., primary, Warren, D., primary, Momtaz, P., primary, Revta, C., primary, Wei, L. J., primary, Iacobelli, M., primary, McDonald, G. B., primary, and Guinan, E. C., primary

Published
2005
Full Text
View/download PDF

66. Rituxan for steroid-refractory chronic GVHD

Author

Cutler, C., primary, Miklos, D., additional, Lee, S.J., additional, Woo, S.-B., additional, Treister, N., additional, Bienfang, D., additional, Klickstein, L., additional, Levin, J., additional, Windawi, S., additional, Pasek, M., additional, Ho, V., additional, Ritz, J., additional, Antin, J., additional, Soiffer, R., additional, and Alyea, E., additional

Published
2005
Full Text
View/download PDF

70. Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation

Author

Bashey, A., primary, Medina, B., additional, Zhong, R.-K., additional, Zhou, J.-H., additional, Carrier, E., additional, Castro, J., additional, Holman, P., additional, Lane, T.A., additional, Sun, C., additional, Lowy, I., additional, Corringham, S., additional, Soiffer, R., additional, Mason, J., additional, and Ball, E.D., additional

Published
2005
Full Text
View/download PDF

71. Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Author

Richardson, Paul G., primary, Soiffer, R. J., additional, Antin, J. H., additional, Voss, S. D., additional, Jin, Z., additional, Kurtzberg, J., additional, Martin, P. L., additional, Hockenbery, D., additional, Murray, K. F., additional, Vogelsang, G. B., additional, Chen, A., additional, Krishnan, A., additional, Kernan, N. A., additional, Avigan, D., additional, Spitzer, T. R., additional, Iannone, R., additional, Giralt, S., additional, Warren, D., additional, Momtaz, P., additional, Bradwin, G., additional, Iacobelli, M., additional, McDonald, G. B., additional, and Guinan, E. C., additional

Published
2004
Full Text
View/download PDF

74. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

Author

Freedman, A S, primary, Neuberg, D, additional, Gribben, J G, additional, Mauch, P, additional, Soiffer, R J, additional, Fisher, D C, additional, Anderson, K C, additional, Andersen, N, additional, Schlossman, R, additional, Kroon, M, additional, Ritz, J, additional, Aster, J, additional, and Nadler, L M, additional

Published
1998
Full Text
View/download PDF

78. A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor. Dana-Farber Cancer Institute, Boston, Massachusetts

Author

Dranoff, G., primary, Soiffer, R., additional, Lynch, T., additional, Mihm, M., additional, Jung, K., additional, Kolesar, K., additional, Liebster, L., additional, Lam, P., additional, Duda, R., additional, Mentzer, S., additional, Singer, S., additional, Tanabe, K., additional, Johnson, R., additional, Sober, A., additional, Bhan, A., additional, Clift, S., additional, Cohen, L., additional, Parry, G., additional, Rokovieh, J., additional, Richards, L., additional, Drayer, J., additional, Berns, A., additional, and Mulligan, R. C., additional

Published
1997
Full Text
View/download PDF

84. Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD.

Author

Chen, Y-B, McDonough, S, Chen, H, Kennedy, J, Illiano, C, Attar, E C, Ballen, K K, Dey, B R, McAfee, S L, Jagasia, M, Soiffer, R, Spitzer, T R, and Ritz, J

Subjects
T cells, HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, BONE marrow transplant complications, GRAFT versus host reaction, LYMPHOCYTES, INTEGRINS
Abstract

Acute intestinal GVHD remains a major source of morbidity after allogeneic hematopoietic cell transplantation (HCT). α4β7 integrin is a cell surface molecule that mediates lymphocyte trafficking to intestinal tissue. In this analysis, peripheral blood was collected at the time of presentation of symptoms of acute GVHD and before any treatment. In all, 45 samples were collected and divided into three groups on the basis of subsequent evaluation: intestinal GVHD (n=15), skin GVHD (n=20) and no GVHD (n=10). Two patients developed intestinal GVHD after DLI. The no-GVHD group comprised 10 patients who presented with suspicious symptoms, but evaluation yielded other etiologies. Analysis by flow cytometry showed that intestinal GVHD patients had a significantly higher percentage of α4β7 integrin-expressing memory CD8+ T cells (median 7.69%; lower and upper quartiles, 1.06% and 11.64%, respectively) compared with patients with skin GVHD (1.26%; 0.57% and 2.49%) and no GVHD (0.96%; 0.44% and 1.85%), P=0.03. No differences were found in α4β7 expression in any CD4+ T-cell subsets or naive CD8+ T cells. This study adds to the evidence that α4β7 integrin is involved in lymphocyte trafficking in acute intestinal GVHD. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

89. 90Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

Author

Abou-Nassar, K E, Stevenson, K E, Antin, J H, McDermott, K, Ho, V T, Cutler, C S, LaCasce, A S, Jacobsen, E D, Fisher, D C, Soiffer, R J, Alyea, E P, Koreth, J, and Freedman, A S

Subjects
LYMPHOMAS, STEM cell transplantation, YTTRIUM, FLUDARABINE, MORTALITY
Abstract

Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more time for GVL effect to develop without the associated toxicity of a myeloablative HSCT. We performed a retrospective study to describe the outcomes of patients with relapsed, refractory or transformed FL who received yttrium-90 (90Y)-ibritumomab tiuxetan followed by fludarabine and low-dose BU RIC allogeneic HSCT at the Dana-Farber Cancer Institute between 2006 and 2009, inclusively. Twelve patients were identified with a median age of 55 (40-66) years and a median number of lines of therapy of 5 (2-10). Two patients (17%) had transformed to a more aggressive histology and five (42%) had chemorefractory FL. Cumulative incidences of grade II-IV acute GVHD at 100 days were 17% (±11%) and chronic GVHD at 12 months were 63% (±19%). Two-year non-relapse mortality was 18% (±12%). Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

95. Partial CD8+T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.

Author

Ho, V. T., Kim, H. T., Li, S., Hochberg, E. P., Cutler, C., Lee, S. J., Fisher, D. C., Milford, E., Kao, G., Daley, H., Levin, J., Ng, A., Mauch, P., Alyea, E. P., Antin, J. H., and Soiffer, R. J.

Subjects
STEM cell transplantation, BONE marrow transplantation, BONE marrow, HOMOGRAFTS, LYMPHOCYTE transformation, TRANSPLANTATION of organs, tissues, etc.
Abstract

Summary:Prior studies suggest that depletion of CD8+T cells from donor bone marrow or donor lymphocyte infusions can reduce graft-versus-host disease (GVHD) without compromising graft-versus-leukemia. We explored CD8 depletion in patients undergoing matched related donor (MRD, n=25) and unrelated donor (URD, n=16) peripheral blood stem cell transplantation following myeloablative conditioning with cyclophosphamide (60?mg/kg/day i.v.×2) and total body irradiation (200?cGy×7 fractions). Ex vivo incubation of mobilized donor peripheral blood cells with anti-CD8 antibody coated high-density microparticles removed 99%of CD8+cells. The median number of CD8+cells infused was 3.9×105 cells/kg (2.2×105 in MRD, and 8.1×105 in URD patients). Post transplant immune suppression included tacrolimus in the MRD cohort, and tacrolimus plus mini-methotrexate (5?mg/m2 days+1, 3, 6, 11) in the URD cohort. All 41 patients engrafted. Grade 2-4 acute GVHD incidence was 61%(44%MRD, 88%URD). Chronic GVHD incidence was 50%(48%MRD, 55%URD). Relapse incidence was 4.9%. Estimated event-free and overall survival rates were 65 and 63%, respectively, at 1 year and 56 and 57%, respectively, at 2 years. There was no correlation between CD8+number and GVHD or survival. A 2-log depletion of CD8+cells from PBSC is insufficient to prevent GVHD.Bone Marrow Transplantation (2004) 34, 987-994. doi:10.1038/sj.bmt.1704690 Published online 18 October 2004 [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

96. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.

Author

Antin, J. H., S. J. Lee, Neuberg, D., Alyea, E., Soiffer, R. J., Sonis, S., and Ferrara, J. L. M.

Subjects
INTERLEUKINS, CYCLOSPORINE, STEM cell transplantation, COMPLICATIONS from organ transplantation
Abstract

Focuses on a study which assessed the administration of rhInterleukin-11 with cyclosporine/MTX prophylaxis after cytoxan/TBI conditioning and allogeneic stem cell transplantation for hematologic malignancies. Analysis of the safety of rules for the prevention of cardiac arrhythmias; Factors that contributed to transplant-related morbidity and mortality; Adverse effects of transplantation on patients.

Published
2002
Full Text
View/download PDF

97. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.

Author

Orsini, E, Alyea, E P, Schlossman, R, Canning, C, Soiffer, R J, Chillemi, A, Neuberg, D, Anderson, K C, and Ritz, J

Subjects
MULTIPLE myeloma, GRAFT versus host disease, BONE marrow transplantation
Abstract

Recent reports of clinical responses following donor lymphocyte infusions (DLI) in patients with relapsed multiple myeloma (MM) after allogeneic BMT have demonstrated the ability of allogeneic cells to mediate a graft-versus-myeloma (GVM) effect, but the mechanisms involved have not been determined. To identify changes in the T cell compartment associated with DLI, we performed a molecular analysis of the T cell receptor (TCR) repertoire in four patients with relapsed MM who received infusions of CD4+ lymphocytes from HLA-identical sibling donors. Three of the four patients demonstrated a clinical anti-myeloma response following DLI but also developed graft-versus-host disease (GVHD). The TCR repertoire was examined after PCR amplification of 24 Vβ gene subfamilies. This method determines the relative utilization of each Vβ gene subfamily and also allows the identification of clonal and oligoclonal T cell populations through analysis of CDR3 regions for each TCR Vβ gene subfamily. Serial blood samples were obtained over at least a 1 year period before and after DLI and results compared to 10 normal donors. Serial analysis of CDR3 size profiles demonstrated the appearance of clonal T cell populations after DLI in each of the three responding patients. The appearance of some clones was noted within the first 3 months after DLI and coincided with decreasing levels of monoclonal paraprotein indicating an ongoing GVM response. Other T cell clones appeared at later time points and coincided with the development of GVHD. These findings demonstrate that T cell clones with different patterns of onset can be identified in the peripheral blood of MM patients following DLI. Further functional characterization of these distinct clonal expansions will be required to determine whether these T cell clones are mediators of either anti-myeloma or anti-host activity. Bone Marrow Transplantation (2000) 25, 623–632. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results